Browse CYP39A1

Summary
SymbolCYP39A1
Namecytochrome P450, family 39, subfamily A, polypeptide 1
Aliases cytochrome P450, subfamily XXXIX (oxysterol 7 alpha-hydroxylase), polypeptide 1; hCYP39A1; Cytochrome P450 3 ......
Chromosomal Location6p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.
Domain PF00067 Cytochrome P450
Function

Involved in the bile acid metabolism. Has a preference for 24-hydroxycholesterol, and converts it into a 7-alpha-hydroxylated product.

> Gene Ontology
 
Biological Process GO:0006066 alcohol metabolic process
GO:0006694 steroid biosynthetic process
GO:0006699 bile acid biosynthetic process
GO:0006706 steroid catabolic process
GO:0006707 cholesterol catabolic process
GO:0007586 digestion
GO:0008202 steroid metabolic process
GO:0008203 cholesterol metabolic process
GO:0008206 bile acid metabolic process
GO:0016042 lipid catabolic process
GO:0016053 organic acid biosynthetic process
GO:0016054 organic acid catabolic process
GO:0016125 sterol metabolic process
GO:0016127 sterol catabolic process
GO:0030573 bile acid catabolic process
GO:0044282 small molecule catabolic process
GO:0044283 small molecule biosynthetic process
GO:0046164 alcohol catabolic process
GO:0046394 carboxylic acid biosynthetic process
GO:0046395 carboxylic acid catabolic process
GO:0072329 monocarboxylic acid catabolic process
GO:0072330 monocarboxylic acid biosynthetic process
GO:1901361 organic cyclic compound catabolic process
GO:1901615 organic hydroxy compound metabolic process
GO:1901616 organic hydroxy compound catabolic process
GO:1902652 secondary alcohol metabolic process
Molecular Function GO:0004497 monooxygenase activity
GO:0005506 iron ion binding
GO:0008387 steroid 7-alpha-hydroxylase activity
GO:0008395 steroid hydroxylase activity
GO:0008396 oxysterol 7-alpha-hydroxylase activity
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0020037 heme binding
GO:0046906 tetrapyrrole binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00120 Primary bile acid biosynthesis
Reactome R-HSA-194068: Bile acid and bile salt metabolism
R-HSA-211859: Biological oxidations
R-HSA-211897: Cytochrome P450 - arranged by substrate type
R-HSA-211976: Endogenous sterols
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-211945: Phase 1 - Functionalization of compounds
R-HSA-192105: Synthesis of bile acids and bile salts
R-HSA-193775: Synthesis of bile acids and bile salts via 24-hydroxycholesterol
Summary
SymbolCYP39A1
Namecytochrome P450, family 39, subfamily A, polypeptide 1
Aliases cytochrome P450, subfamily XXXIX (oxysterol 7 alpha-hydroxylase), polypeptide 1; hCYP39A1; Cytochrome P450 3 ......
Chromosomal Location6p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CYP39A1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCYP39A1
Namecytochrome P450, family 39, subfamily A, polypeptide 1
Aliases cytochrome P450, subfamily XXXIX (oxysterol 7 alpha-hydroxylase), polypeptide 1; hCYP39A1; Cytochrome P450 3 ......
Chromosomal Location6p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CYP39A1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCYP39A1
Namecytochrome P450, family 39, subfamily A, polypeptide 1
Aliases cytochrome P450, subfamily XXXIX (oxysterol 7 alpha-hydroxylase), polypeptide 1; hCYP39A1; Cytochrome P450 3 ......
Chromosomal Location6p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CYP39A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.0370.00917
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1380.86
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.7070.0012
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2350.52
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4070.697
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0220.985
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1360.814
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4670.605
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1340.896
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.5660.122
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.0740.404
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3980.0607
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CYP39A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.75.5-1.81
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 014014.3-14.31
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCYP39A1
Namecytochrome P450, family 39, subfamily A, polypeptide 1
Aliases cytochrome P450, subfamily XXXIX (oxysterol 7 alpha-hydroxylase), polypeptide 1; hCYP39A1; Cytochrome P450 3 ......
Chromosomal Location6p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CYP39A1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCYP39A1
Namecytochrome P450, family 39, subfamily A, polypeptide 1
Aliases cytochrome P450, subfamily XXXIX (oxysterol 7 alpha-hydroxylase), polypeptide 1; hCYP39A1; Cytochrome P450 3 ......
Chromosomal Location6p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CYP39A1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CYP39A1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCYP39A1
Namecytochrome P450, family 39, subfamily A, polypeptide 1
Aliases cytochrome P450, subfamily XXXIX (oxysterol 7 alpha-hydroxylase), polypeptide 1; hCYP39A1; Cytochrome P450 3 ......
Chromosomal Location6p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CYP39A1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCYP39A1
Namecytochrome P450, family 39, subfamily A, polypeptide 1
Aliases cytochrome P450, subfamily XXXIX (oxysterol 7 alpha-hydroxylase), polypeptide 1; hCYP39A1; Cytochrome P450 3 ......
Chromosomal Location6p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CYP39A1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCYP39A1
Namecytochrome P450, family 39, subfamily A, polypeptide 1
Aliases cytochrome P450, subfamily XXXIX (oxysterol 7 alpha-hydroxylase), polypeptide 1; hCYP39A1; Cytochrome P450 3 ......
Chromosomal Location6p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CYP39A1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCYP39A1
Namecytochrome P450, family 39, subfamily A, polypeptide 1
Aliases cytochrome P450, subfamily XXXIX (oxysterol 7 alpha-hydroxylase), polypeptide 1; hCYP39A1; Cytochrome P450 3 ......
Chromosomal Location6p12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CYP39A1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.